DDR1 modulators show therapeutic promise in cancer and fibrosis, facing challenges in selectivity and pharmacokinetics
Background
The discoidin domain receptor 1 (DDR1) is a unique collagen-activated receptor tyrosine kinase crucial for cell proliferation, survival, adhesion, and matrix remodeling. Its dysregulation is strongly implicated in various pathologies, including cancer, tissue fibrosis, atherosclerosis, and inflammatory diseases. Traditional therapeutic approaches often fall short in addressing the complex roles of DDR1, especially its non-catalytic functions which are critically involved in tumor progression, metastasis, and immune exclusion. Selectively targeting DDR1's catalytic and/or non-catalytic functions presents a promising strategy to overcome these therapeutic gaps.
Study Design
This comprehensive review systematically summarized the advancements in DDR1 modulators developed between 2020 and 2025. The authors focused on three primary classes of therapeutic agents: small-molecule inhibitors, degraders, and biomolecules. The review evaluated their mechanisms of action, potential therapeutic applications, and current developmental status. It specifically highlighted efforts to selectively inhibit DDR1's catalytic activity, block its non-catalytic functions, or induce its degradation, providing an updated perspective on the landscape of DDR1-targeting strategies.
Results
Significant progress has been made in developing small-molecule DDR1 kinase inhibitors, though achieving high selectivity against other kinases remains a considerable challenge. Novel degraders have emerged, designed to inhibit both the catalytic and non-catalytic functions of DDR1, offering a conceptual advantage over traditional kinase inhibitors. However, these degraders currently suffer from suboptimal pharmacokinetic (PK) properties. > Alternatively, biologics, including antibodies and peptides, effectively block the DDR1-collagen interaction, specifically inhibiting non-catalytic signaling, with one antibody currently under clinical evaluation. The review underscores that while various modulation strategies exist, each faces distinct hurdles in translation. Efforts are ongoing to refine these approaches, particularly in improving selectivity for inhibitors and enhancing the PK profiles of degraders.
Key Findings
- Small-molecule DDR1 kinase inhibitors show progress but struggle with high selectivity.
- DDR1 degraders inhibit both catalytic and non-catalytic functions, but have suboptimal pharmacokinetics.
- Biologics (antibodies, peptides) block DDR1-collagen interaction, specifically targeting non-catalytic signaling.
- One DDR1-targeting antibody is currently under clinical evaluation.
- Future development hinges on improving inhibitor selectivity and degrader pharmacokinetics.
Why It Matters
This review clarifies the evolving landscape of DDR1 targeting, emphasizing that a multi-pronged approach is needed to tackle diseases like cancer and fibrosis. For researchers and biohackers exploring novel therapeutic avenues, the distinction between catalytic and non-catalytic DDR1 inhibition is crucial, suggesting that agents like degraders or biologics (e.g., peptides) might offer broader efficacy than kinase inhibitors alone. Developing highly selective DDR1 inhibitors and improving the pharmacokinetic profiles of degraders are pivotal next steps for translating these promising strategies into viable clinical therapies. The clinical evaluation of a DDR1-targeting antibody indicates that this mechanism is moving closer to patient application, potentially opening new treatment paradigms.
ddr1
receptor-tyrosine-kinase
cancer
fibrosis
inflammation
drug-development